Objective To study the clinical characteristics, the laboratory profile (CD4+ and CD8+ counts and CD4+/CD8+ ratio) and the efficacy of antifungal treatment in HIV/AIDS patients with oropharyngeal candidiasis. Methods Oral lesions were evaluated among 20 HIV/AIDS patients with oropharyngeal candidiasis and the controls who were HIV-negative patients with oropharyngeal candidiasis. Samples were obtained from the lesions for fungal examination by microscopy and culture. The flow cytometry was used for detection of CD4+ and CD8+ counts in peripheral blood. Treatment efficacy of itraconazole was assessed among study group and the control group after treatment for one week, two weeks, at the end of treatment, as well as two weeks after treatment. Results Out of 20 HIV/AIDS patients, 19 were infected with Candida albicans and one with Candida parapsilosis. Six cases had infection on the tongue and 14 on the mucous membrane of oral cavity. CD4+ and CD8+ counts, and CD4/CD8 ratio were 119.40?127.43, 652.50?338.57 and 0.163?0.13, respectively. Mycologic clearance rates were 16.67%, 50.00%, 61.11% and 66.67%, respectively, after treatment with itraconazole for one week, two weeks, at the end of treatment, and two weeks after treatment. Conclusions Oropharyngeal candidiasis is a complication occurred in HIV/AIDS patients, and Candida albicans is the most common pathogen of the infection. The tongue and mucous membrane of oral cavity are usually involved in the patients. The therapeutic efficacy is related to the status of immunity.

Brexanolone, also known as 3a, 5a-tetrahydroprogesterone, is a metabolite of progesterone and an important neuroactive steroid with a wide range of biological activities.Recently, the most exciting thing is that 2019 year the FDA has approved its treatment of postpartum depression, which is also the only drug to obtain indications for postpartum depression.It is expected to officially enter the market by the end of June 2019 year.This article reviews the research progress of its pharmacological action.

Bacteriophages bind to the bacteria receptor through the receptor binding proteins (RBPs), a process that requires the involvement of complex atomic structures and conformational changes. In response to bacteriophage infection, bacteria have developed a variety of resistance mechanisms, while bacteriophages have also evolved multiple antagonistic mechanisms to escape host resistance. The exploration of the "adsorption-anti adsorption-escape process" between bacteriophages and bacteria helps us better understand the co-evolution process of bacteriophages and bacteria, which is important for the development of phage therapeutic technologies and phage-based biotechnologies. This review summarizes the bacteriophage adsorption related proteins, how bacteriophages escape host resistance based on the RBP alternations, and the recent progress of RBP-related biotechnologies.
Bacteria ; Bacteriophage Receptors ; Bacteriophages/genetics* ; Carrier Proteins ; Protein Binding